ACRO Biomedical, a company highly recognized by the public with its biomedical technology, has received many good news in the second half of year 2020. After completing the cash capital increase of the original shareholders in the third quarter, ACRO Biomedical received an USA patent, “Preparation of high purity collagen particles and uses thereof” at the beginning of the fourth quarter. Receiving this patent will help with accelerating overall revenue growth and will have a positive effect on ACRO’s upcoming plan of becoming a listed company.

ACRO has received 12 other patents globally. The patent of “Acellular corneas, methods of producing the same and uses thereof” has been granted by Taiwan, USA, Japan, Korea, and EU. The patent of “Preparation of acellular cartilage graft and uses thereof” has been granted by Taiwan, Japan, and Korea. In addition, there are more than 30 patents under review, which shows ACRO’s great capability.

https://www.chinatimes.com/newspapers/20201204000445-260210?chdtv